UCP: Utrecht Cardiovascular Pharmacogenetics
This set of case-control studies conducted by the UCP team of researchers examined gene-drug interactions for cardiovascular drugs and the risk of myocardial infarction. Data were collected from the Dutch population-based registry of pharmacy records linked to hospital discharge records (PHARMO). Prior to collecting data from the PHARMO registry, they demonstrated feasibility of selecting patients from a coded database for a pharmacogenetic study and were able to approach them through community pharmacies, achieving reasonable response rates and without violating privacy rules. Using this registry, they found the Gly460Trp variant of the alpha-adducin gene, although previously associated with the salt-sensitive and diuretic responsive form of hypertension, does not play an important role in modifying the risk of nonfatal MI associated with the use of thiazide diuretics. A second case-control study in patients with hypercholesterolemia found that common genetic variability within the SLCO1B1 and ABCB1 genes is associated with the modification of the effectiveness of statins in the prevention of the clinical outcome, myocardial infarction. This was the first study to demonstrate this association.
Observational cohort, including 3818 whites. Data set consists of patients who:
- received a prescription for an antihypertensive drug
- had hypercholesterolemia (prescription for a cholesterol-lowering drug or total cholesterol >5.0 mmol/l)
- having both conditions under 1 and 2
4. were diagnosed with (incident) diabetes type 2
- Anke-Hilse Maitland-van der Zee, Utrecht University, Principal Investigator
- Olaf Klungel, Utrecht University